RET and medullary thyroid gland carcinoma: The following ORRs were observed: 71% in treatment-naïve MTC patients, 60% in MTC patients with prior cabozantinib and/or vandetanib, and 89% in previously treated RET fusion-positive thyroid cancer patients [153].